Xponance Inc. Sells 1,088 Shares of CVS Health Co. (NYSE:CVS)

Xponance Inc. lowered its stake in shares of CVS Health Co. (NYSE:CVS) by 0.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 174,964 shares of the pharmacy operator’s stock after selling 1,088 shares during the quarter. Xponance Inc.’s holdings in CVS Health were worth $13,815,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in CVS. Live Oak Investment Partners acquired a new stake in CVS Health in the fourth quarter worth about $25,000. Atticus Wealth Management LLC boosted its holdings in CVS Health by 149.0% in the fourth quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock worth $29,000 after acquiring an additional 219 shares in the last quarter. Cornerstone Planning Group LLC boosted its holdings in CVS Health by 111.5% in the third quarter. Cornerstone Planning Group LLC now owns 461 shares of the pharmacy operator’s stock worth $32,000 after acquiring an additional 243 shares in the last quarter. PCA Investment Advisory Services Inc. acquired a new stake in CVS Health in the second quarter worth about $37,000. Finally, ZRC Wealth Management LLC boosted its holdings in CVS Health by 400.0% in the fourth quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator’s stock worth $39,000 after acquiring an additional 400 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Price Performance

Shares of CVS Health stock traded up $0.34 on Friday, reaching $69.07. The company’s stock had a trading volume of 758,308 shares, compared to its average volume of 10,760,354. The company has a market capitalization of $87.06 billion, a P/E ratio of 10.74, a PEG ratio of 0.91 and a beta of 0.52. CVS Health Co. has a 52-week low of $64.41 and a 52-week high of $83.25. The stock has a 50-day moving average price of $75.42 and a 200-day moving average price of $73.70. The company has a quick ratio of 0.63, a current ratio of 0.86 and a debt-to-equity ratio of 0.77.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, February 7th. The pharmacy operator reported $2.12 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.11. The business had revenue of $93.81 billion during the quarter, compared to analysts’ expectations of $90.58 billion. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. The business’s revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.99 earnings per share. Analysts expect that CVS Health Co. will post 8.32 EPS for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Monday, April 22nd will be given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.85%. The ex-dividend date of this dividend is Friday, April 19th. CVS Health’s payout ratio is 41.18%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $87.00 price objective on shares of CVS Health in a research note on Wednesday, April 10th. HSBC assumed coverage on CVS Health in a research note on Friday, December 22nd. They issued a “buy” rating and a $94.00 price objective for the company. StockNews.com cut CVS Health from a “buy” rating to a “hold” rating in a research note on Thursday, February 15th. SVB Leerink assumed coverage on CVS Health in a research note on Monday, February 26th. They issued an “outperform” rating and a $88.00 price objective for the company. Finally, Wells Fargo & Company reduced their price target on CVS Health from $83.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 8th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $89.44.

Insider Buying and Selling

In related news, EVP Prem S. Shah sold 29,473 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the completion of the sale, the executive vice president now directly owns 39,765 shares in the company, valued at $3,059,916.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.24% of the stock is owned by company insiders.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.